Tirzepatide for heart health in people with overweight or obesity
Treatments studied
Part of Heart & circulation, Hormones & metabolism, Pain clinical trials.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your body mass index (BMI) is 27 or higher.
- You are scheduled for a coronary angiogram (a heart artery X-ray) because of stable chest pain.
- The angiogram shows fatty plaque buildup (atheromatosis) in at least one heart artery, and a special test (NIRS) finds a high lipid core burden index (LCBI4mm > 200) in a vessel that won’t be opened with a stent.
- You do not have diabetes (HbA1c less than 6.5%) and you are not currently taking a GLP-1 medication (like Ozempic or Wegovy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether tirzepatide, a medication that helps with weight loss and blood sugar control, can improve the ability to exercise and daily function in people who have heart failure with reduced pumping strength and are overweight or obese.
This study tests whether combining a weight-loss medication called tirzepatide (also known as Mounjaro) with a supervised exercise program helps people lose weight and improve their overall health. You'll be in the study for about four months, and you'll get support and monitoring.
This study tests whether the medicine tirzepatide can help adults who are overweight or obese and have congenital heart disease (a heart condition present from birth) lose weight safely. The medicine may also improve heart health and metabolism. It is for people who have already tried diet and exercise for at least a year without much weight loss.
This study tests a medicine called tirzepatide to see if it helps people with overweight or obesity lose weight, whether or not they also have type 2 diabetes. Tirzepatide is given as an injection and works on hormones that control appetite.
This Phase 2 study tests whether tirzepatide can improve how your body handles fat (especially in people with overweight or obesity) and reduce fat-related “lipotoxicity.” It may help with body fat function and related health markers, but you must meet specific health and medication rules.
This trial tests if tirzepatide is more effective than standard obesity treatments for adults who have a BMI between 30 and 35 and one weight-related health condition, but do not have diabetes. The goal is to help you lose weight.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.